<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03822130</url>
  </required_header>
  <id_info>
    <org_study_id>IR2018001142</org_study_id>
    <nct_id>NCT03822130</nct_id>
  </id_info>
  <brief_title>Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate for Unresectable Gastric Cancer</brief_title>
  <official_title>A Randomized Controlled Trial for Intra-arterial Infusion Chemotherapy Combined With Sodium Bicarbonate and Systemic Chemotherapy for Unresectable Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project intends to compare the clinical effects and side effects of three kinds of
      treatment methods in the treatment of unresectable gastric cancer by intra-arterial catheter
      infusion chemotherapy combined with sodium bicarbonate and systemic chemotherapy. It is clear
      that intra-arterial catheter infusion chemotherapy combined with sodium bicarbonate is not
      suitable for the treatment of unresectable gastric cancer. The clinical practice value of
      resection of gastric cancer can provide high quality evidence-based medical basis for the
      treatment guidelines of advanced gastric cancer, and explore a new clinical technology with
      exact curative effect and higher safety.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Successful conversion rate of operation</measure>
    <time_frame>42 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>42 days</time_frame>
    <description>Objective Response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months</time_frame>
    <description>progression-free survival</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Successful Conversion Rate of Operation</condition>
  <condition>Unresectable Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Systemic Chemotherapy + Oral Chemotherapy Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arterial catheter infusion chemotherapy plus oral chemotherapy group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arterial catheter infusion chemotherapy + sodium bicarbonate plus oral chemotherapy group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arterial catheter infusion chemotherapy</intervention_name>
    <description>Arterial catheter infusion chemotherapy</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Bicarbonate</intervention_name>
    <description>Arterial catheter infusion Sodium Bicarbonate</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Systemic Chemotherapy</intervention_name>
    <description>Systemic Chemotherapy</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Chemotherapy</intervention_name>
    <description>Oral Chemotherapy</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients aged 18 to 75 years;

          2. Ultrasound gastroscopy or imaging (CT) can diagnose potentially unresectable gastric
             cancer (T4a-bN2-3M0) with indications of neoadjuvant chemotherapy or transformation
             therapy;

          3. Pathological diagnosis of gastric cancer;

          4. No contraindication of chemotherapy;

          5. Patients who did not undergo chemotherapy or were diagnosed for the first time.

        Exclusion Criteria:

          1. Those who fail to comply with the requirements of the trial, obviously violate this
             regimen, or change to other regimens in the course of treatment;

          2. The life expectancy of patients with extensive systemic metastasis is less than 3
             months;

          3. Leukocyte count is less than 2*109/L and platelet count is less than 75*10^9/L;

          4. Severe heart, liver and kidney diseases, unable to tolerate chemotherapy;

          5. Patients without gastric cancer complications such as massive gastrointestinal
             bleeding and perforation need to be treated in emergency department;

          6. Patients with distant metastasis (excluding group 16 lymph node metastasis);

          7. Patients with other tumors, with a history of malignant tumors (excluding early
             primary cancers);

          8. The patient himself asked to withdraw from the trial;

          9. Researchers believe that patients are not suitable for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming Chao</last_name>
    <phone>+86 13957139239</phone>
    <email>z2doctor_chaoming@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Second affiliated Hospital, Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Chao</last_name>
      <phone>+86 13957139239</phone>
      <email>z2doctor_chaoming@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 23, 2019</study_first_submitted>
  <study_first_submitted_qc>January 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2019</study_first_posted>
  <last_update_submitted>February 18, 2019</last_update_submitted>
  <last_update_submitted_qc>February 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

